LICENSE AGREEMENTLicense Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Florida
This License Agreement (the “Agreement”) is entered into and made effective the 20th day of September, 1999 (the “Effective Date”) between UNIVERSITY OF MIAMI and its School of Medicine, whose principal place of business is at 1600 N.W. 10th Avenue, Miami, Florida 33136 (hereinafter referred to as “LICENSOR”) and Seattle Genetics, Inc., whose principal place of business is at 22215 26th Avenue S.E., Suite 3000, Bothell, Washington 98021, hereinafter referred to as “LICENSEE”).
LICENSE AGREEMENT No. 651-O1.LICLicense Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Arizona
THIS AGREEMENT (the “Agreement”), made this 3rd day of February, 2000 (the “EFFECTIVE DATE”), is by and between the ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona, acting on behalf of and for ARIZONA STATE UNIVERSITY, of Tempe, Arizona (“ASU”) and Seattle Genetics, Inc., a corporation organized under the laws of Delaware having its principal place of business located at 22215 26th Avenue SE, Bothell, Washington 98021 (“LICENSEE”).
NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
This Non-exclusive License Agreement (the “Agreement”), effective as of October 16th, 2000 (The “Effective Date”), is entered into by and between ICOS Corporation, a Delaware corporation having offices at 22021 20th Avenue SE, Bothell, WA 98021, U.S.A., (“ICOS”), and Seattle Genetics, Inc., a Delaware corporation having offices at 22215 26th Avenue S.E., Suite 300, Bothell, WA 98021 (“LICENSEE”). All references to LICENSEE in this Agreement shall include its Affiliates (as such term is defined below).
July 29, 1999Seattle Genetics Inc /Wa • November 26th, 2010 • Biological products, (no disgnostic substances)
This letter sets forth the agreement of Bristol-Myers Squibb Company (“BMS”) and Seattle Genetics, Inc. (“SGI”) to amend that certain License Agreement dated March 30, 1998 between BMS and SGI (the “Agreement”) as set forth herein.
FIRST AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
This First Amendment (the “Amendment”) to the License Agreement (“License Agreement”) is made effective as of January 31, 2000 (the “Effective Date”) by and between MABTECH AB, formed under the laws of Sweden (“MAB”) and SEATTLE GENETICS, INC., a Delaware corporation (“SGI”).
LICENSE AGREEMENT BETWEEN BRISTOL-MYERS SQUIBB AND COMPANY SEATTLE GENETICS, INC. DATED AS OF MARCH 30, 1998License Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (this “Agreement”) dated as of March 30, 1998 by and between Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the State of Delaware, having offices at P.O. Box 4000, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, for and on behalf of itself and its Affiliates (“BMS”), and Seattle Genetics, Inc., a corporation duly organized and existing under the laws of the State of Delaware, having offices at 22215 26th Avenue, SE, Bothell, Washington 98021 (“SGI”).
LICENSE AGREEMENTLicense Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
This License Agreement (this “Agreement”), is entered into as of June 14, 1998 (the “Effective Date”) by and between MABTECH AB, formed under the laws of Sweden (“MAB”) and SEATTLE GENETICS, INC., a Delaware corporation (“SGI”).
AMENDMENT NO. 1 TO LICENSE AGREEMENT BETWEEN UNIVERSITY OF MIAMI AND SEATTLE GENETICS, INC.License Agreement • November 26th, 2010 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
This Amendment No. 1 to License Agreement (the “Amendment”) is made as of August 4, 2000 by and between University of Miami and its School of Medicine, whose principal place of business is at 1600 N.W. 10th Avenue, Miami, Florida 33136 (“Licensor”), and Seattle Genetics, Inc., a Delaware corporation having offices at 22215 26th Avenue SE, Bothell, WA 98021 (“Licensee”).
